Abstract
Intraprostatic fiducial markers may be used to localize the prostate for delivery of external beam radiation therapy (RT). The reliability of this technique is dependent upon a stable geometry of markers within the prostate to accurately reflect the prostate’s position. Since androgen suppression therapy may reduce the prostate volume, marker geometry may subsequently change. This analysis compares the stability of electromagnetic transponders within the prostate in patients treated with and without neoadjuvant ± concurrent androgen suppression therapy (AST).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
